Health Care & Life Sciences » Pharmaceuticals | Hanmi Pharmaceutical Co. Ltd.

Hanmi Pharmaceutical Co. Ltd. | Mutual Funds

Mutual Funds that own Hanmi Pharmaceutical Co. Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total International Stock Index Fund
97,878
0.86%
1,980
0.01%
07/31/2018
Government Pension Fund - Global (The)
63,297
0.56%
-69,203
0%
12/31/2017
iShares Core MSCI Emerging Markets ETF
52,543
0.46%
0
0.05%
09/05/2018
50,451
0.44%
3,022
1%
06/30/2017
iShares MSCI South Korea Capped ETF
39,191
0.34%
0
0.45%
09/06/2018
Vanguard Developed Markets Index Fund
38,517
0.34%
0
0.02%
07/31/2018
iShares MSCI Emerging Markets ETF
37,433
0.33%
0
0.05%
09/06/2018
Mirae Asset TIGER 200
25,191
0.22%
798
0.4%
01/31/2018
DFA Emerging Markets Core Equity Portfolio
24,401
0.21%
-5,982
0.04%
04/30/2018
CREF Stock Account
20,510
0.18%
0
0.01%
03/31/2018

About Hanmi Pharmaceutical Co.

View Profile
Address
214 Muha-ro
Hwaseong GY 18536
Korea, Republic Of
Employees -
Website http://www.hanmipharm.com
Updated 07/08/2019
Hanmi Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for high blood pressure, hyperlipidemia, reflux esophagitis, and cerebrovascular disease. The company was founded by Lim Sung-Gi on June 15, 1973 and is headquartered in Hwaseong-si, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.